Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Germany
/
Pharmaceuticals & Biotech
Create a narrative
Bayer
XTRA:BAYN Community
1
Narratives
written by author
1
Comments
on narratives written by author
223
Fair Values set
on narratives written by author
Create a narrative
Bayer
Popular
Undervalued
Overvalued
Bayer
WA
Analyst Price Target
Consensus Narrative from 20 Analysts
Launches Of Nubeqa And Preceon Corn Will Strengthen Future Performance
Key Takeaways Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues. Organizational transformation and litigation efforts are expected to enhance profitability and stabilize cash flow.
View narrative
€27.71
FV
20.4% undervalued
intrinsic discount
1.22%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
33
users have followed this narrative
23 days ago
author updated this narrative
Your Valuation for
BAYN
Bayer
Your Fair Value
€
Current Price
€22.05
82.5% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-16b
50b
2015
2018
2021
2024
2025
2027
2030
Revenue €49.4b
Earnings €7.3b
Advanced
Set as Fair Value